L-Nutra
  • About us
    • About L-Nutra
    • Italian Team
  • Fasting Mimicking Diet
  • Scientific research
    • Scientific Articles
    • List of Clinical Trials
  • Products
    • ProLon
    • Fast Bar
  • Newsroom
  • Contact Us
  • Search
  • Menu
L-Nutra News

ProLon® celebrates second year anniversary with the announcement of a new major patent and more than 80,000 impacted consumers lives

https://l-nutra.eu/wp-content/uploads/2018/09/2-year-anniversary.jpg 285 352 wpadmin https://l-nutra.eu/wp-content/uploads/2019/07/Logo_LN_Ita.png wpadmin2018-09-24 19:44:182018-09-24 19:52:26ProLon® celebrates second year anniversary with the announcement of a new major patent and more than 80,000 impacted consumers lives

Via XX Settembre, 12/2E - 16121
GENOVA (GE), ITALIA P.I 02140480993

(+39) 3271180483

FOLLOW US

facebook twitter youtube linkedin

HEALTH CARE PROVIDERS

Health Care Providers interested in authorizing ProLon® for their patients can Register on the their national ProLon® website.

DISCLAIMER

The statements on this site have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease.

PEOPLE AFFECTED BY DIABETES

WARNING RELATED TO OUR RECENT STUDIES ON DIABETES: DO NOT TRY TO APPLY ANY TYPE OF FASTING MIMICKING DIET TO TREAT EITHER TYPE 1 OR TYPE 2 DIABETES ALONE OR EVEN WITH THE HELP OF A DOCTOR. THE COMBINATION OF THE FMD AND INSULIN BUT ALSO OTHER DRUGS COULD CAUSE SEVERE PROBLEMS. ALTHOUGH THE USE OF THE FMD TO TREAT EITHER TYPE 1 OR 2 DIABETES IS PROMISING, IT MUST BE FIRST TESTED AND PROVEN EFFECTIVE IN FDA CLINICAL TRIALS WHICH WILL PROBABLY REQUIRE HOSPITALIZATION DURING THE TREATMENT.

Copyright © L-Nutra Inc.
Scroll to top

This site uses cookies. By continuing to browse the site, you are agreeing to our use of cookies.

OK